RESUMEN
Zika virus (ZIKV), a recently emerged member of the flavivirus family, forms replication compartments at the ER during its lifecycle. The proteins that are responsible for the biogenesis of replication compartments are not well defined. Here, we show that Zika nonstructural protein 1 (NS1)-induced ER remodeling is essential for viral replication. NS1 expressed in the ER lumen induced ER perinuclear aggregation with an ultrastructure resembling that of the replication compartment. Data from model membrane system indicated that the membrane-binding and membrane-remodeling properties of NS1 depend on its hydrophobic insertion into the membrane. These findings demonstrate that NS1 plays a crucial role in flavivirus replication compartment formation by remodeling the ER structure.
Asunto(s)
Proteínas no Estructurales Virales/genética , Replicación Viral/genética , Infección por el Virus Zika/genética , Virus Zika/genética , Retículo Endoplásmico/genética , Retículo Endoplásmico/virología , Humanos , Virus Zika/patogenicidad , Infección por el Virus Zika/virologíaRESUMEN
Induction of interferons (IFNs) is a central event of antiviral innate immunity. As crucial posttranscriptional regulators, microRNAs (miRNAs) are important for IFN-mediated host defense. Although screening has indicated a substantial number of miRNAs to be differentially expressed after IFN stimulation, the detailed mechanisms of these miRNAs in the antiviral response are underexplored and of great significance. Here, we show that hsa-miR-1225-3p is specifically down-regulated by type I IFN through the IFN/JAK/STAT signaling pathway. Silencing endogenous miR-1225-3p inhibited infection by multiple IFN-susceptible viruses, including hepatitis C virus, Sendai virus, and Newcastle disease virus. In contrast, overexpression of miR-1225-3p impaired the antiviral effect of IFNs and facilitated viral infection. Regarding the mechanism, we identified growth factor receptor-bound protein 2-associated binding protein 3 (GAB3) as a direct target of miR-1225-3p. GAB3 expression was up-regulated by IFN, and overexpression of GAB3 demonstrated potent antiviral effects through enhancing IFN response and virus-triggered innate immune activation. Taken together, our findings reveal the biological function of miR-1225-3p for the first time and propose a novel antiviral regulation pathway in which miRNA and GAB3 participate. This study contributes to the understanding of host miRNA participation in antiviral processes of IFN.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Antivirales/farmacología , Regulación hacia Abajo/efectos de los fármacos , Interferones/farmacología , MicroARNs/genética , Proteínas Adaptadoras Transductoras de Señales/inmunología , Línea Celular , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Inmunidad Innata/efectos de los fármacos , MicroARNs/inmunología , Transducción de Señal/efectos de los fármacosRESUMEN
Sterol regulatory element binding proteins (SREBPs) are master regulators of hepatic lipid homeostasis. Aberrant expression of SREBPs frequently leads to lipid metabolism dysregulation. Long non-coding RNAs (lncRNAs) have been identified with diverse biological functions, but the effects of lncRNAs on lipid metabolism are rarely reported. Here, we identified a novel human specific lncRNA, lncHR1, as a negative regulator of SREBP-1c expression. Overexpression of lncHR1 inhibited expression of SREBP-1c and fatty acid synthase (FAS) and then repressed oleic acid-induced hepatic cell triglyceride (TG) and lipid droplet (LD) accumulation. In vivo, the data of established transgenic animals showed that mice with lncHR1 expression had less hepatic expression of SREBP-1c, FAS, Acetyl-CoA carboxylase α (ACCα), and less hepatic and plasma TG after being fed a high-fat diet. Therefore, we report a novel lncRNA which can decrease lipid metabolism by repressing SREBP-1c gene expression.
Asunto(s)
Hígado/metabolismo , ARN Largo no Codificante/metabolismo , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/metabolismo , Animales , Western Blotting , Línea Celular Tumoral , Hepacivirus/patogenicidad , Humanos , Hibridación Fluorescente in Situ , Metabolismo de los Lípidos/genética , Metabolismo de los Lípidos/fisiología , Hígado/patología , Hígado/virología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , ARN Largo no Codificante/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/genética , Triglicéridos/sangre , Triglicéridos/metabolismoRESUMEN
Tight junctions (TJs) are the outermost structures of intercellular junctions and are highly specialized membrane domains involved in many important cellular processes. However, most TJ proteins are four-time transmembrane proteins and are difficult to express in their correct soluble form, which limits their functional study and therapeutic application. Human occludin (OCLN) is a major component of TJs and an essential co-receptor for hepatitis C virus (HCV) cell entry. To explore expression strategy for recombinant TJ proteins possessing integrated and functional extracellular loops, OCLN was here used as a model molecule, and several prokaryotic fusion constructs were designed by docking OCLN extracellular loops (ECLs) to HIV-1 gp41 NHR and CHR six-helical bundle (6HV1); then their biophysical features and anti-HCV activity were evaluated. The proteins were successfully expressed and purified in E. coli, and the double-loop constructs (D1ECL1S+D2ECL2 as a representative) were found to have more potent HCV neutralizing activity than single-loop constructs at non-cytotoxic concentrations. Circular dichroism studies indicate that D1ECL1S+D2ECL2 adopt stable α-helical folds consistent with design. Thermal denaturation assay indicated that D1ECL1S+D2ECL2 is highly stable at 80°C (melting temperature, Tm, of 89.08 ± 2.0°C) and comparable in stability to the 6HV1 scaffold. Moreover, the time-of-addition experiment revealed that D1ECL1S+D2ECL2 predominantly functioned during the early stages of HCV entry. Taken together, these findings provide a novel strategy for recombinant TJ protein expression in vitro, which may shed light on functional and structural studies for TJs and may provide a new avenue to drug development.
Asunto(s)
Espacio Extracelular/metabolismo , Proteína gp41 de Envoltorio del VIH/química , Ocludina/genética , Ocludina/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Uniones Estrechas/metabolismo , Línea Celular , Expresión Génica , Proteína gp41 de Envoltorio del VIH/genética , VIH-1/genética , Hepacivirus/efectos de los fármacos , Hepacivirus/fisiología , Humanos , Simulación del Acoplamiento Molecular , Ocludina/farmacología , Conformación Proteica en Hélice alfa , Proteínas Recombinantes de Fusión/farmacología , Internalización del Virus/efectos de los fármacosRESUMEN
Hepatitis C virus (HCV) envelope proteins E1 and E2 play an essential role in virus entry. However, the fusion mechanisms of HCV remain largely unclear, hampering the development of efficient fusion inhibitors. Here, we developed two cell-based membrane fusion models that allow for screening a peptide library covering the full-length E1 and E2 amino acid sequences. A peptide from the E2 stem domain, named E27, was found to possess the ability to block E1E2-mediated cell-cell fusion and inhibit cell entry of HCV pseudoparticles and infection of cell culture-derived HCV at nanomolar concentrations. E27 demonstrated broad-spectrum inhibition of the major genotypes 1 to 6. A time-of-addition experiment revealed that E27 predominantly functions in the late steps during HCV entry, without influencing the expression and localization of HCV co-receptors. Moreover, we demonstrated that E27 interfered with hetero-dimerization of ectopically expressed E1E2 in cells, and mutational analysis suggested that E27 might target a conserved region in E1. Taken together, our findings provide a novel candidate as well as a strategy for developing potent and broad-spectrum HCV fusion inhibitors, which may complement the current direct-acting antiviral medications for chronic hepatitis C, and shed light on the mechanism of HCV membrane fusion.
Asunto(s)
Antivirales/metabolismo , Hepacivirus/efectos de los fármacos , Hepacivirus/fisiología , Péptidos/metabolismo , Proteínas del Envoltorio Viral/metabolismo , Inhibidores de Proteínas Virales de Fusión/metabolismo , Internalización del Virus/efectos de los fármacos , Línea Celular , Hepatocitos/virología , HumanosRESUMEN
Hepatitis C virus (HCV) infects 130 million people worldwide and is a leading cause of liver cirrhosis, end-stage liver disease and hepatocellular carcinoma. The interactions between viral elements and host factors play critical role on HCV invade, replication and release. Here, we identified adaptor protein complex 1 sigma 3 subunit (AP1S3) as a dependency factor for the efficient HCV infection in hepatoma cells. AP1S3 silencing in cultivated Huh7.5.1 cells significantly reduced the production of HCV progeny particles. Immunoprecipitation analysis revealed that AP1S3 interacted with the HCV E2 protein. With this interaction, AP1S3 could protect HCV E2 from ubiquitin-mediated proteasomal degradation. Using in vivo ubiquitylation assay, we identified that E6-Associated Protein (E6AP) was associated with HCV E2. In addition, treatment with synthetic peptide that contains the AP1S3-recognized motif inhibited HCV infection in Huh7.5.1 cells. Our data reveal AP1 as a novel host network that is required by viruses during infection and provides a potential target for developing broad-spectrum anti-virus strategies.
Asunto(s)
Subunidades sigma de Complejo de Proteína Adaptadora/metabolismo , Hepacivirus/fisiología , Interacciones Huésped-Patógeno , Proteínas del Envoltorio Viral/metabolismo , Subunidades sigma de Complejo de Proteína Adaptadora/deficiencia , Subunidades sigma de Complejo de Proteína Adaptadora/genética , Carcinoma Hepatocelular/virología , Línea Celular Tumoral , Silenciador del Gen , Hepacivirus/efectos de los fármacos , Humanos , Inmunoprecipitación , Neoplasias Hepáticas/virología , Péptidos/síntesis química , Péptidos/farmacología , Complejo de la Endopetidasa Proteasomal/metabolismo , ARN Viral , Ubiquitina/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo , Ensamble de VirusRESUMEN
Hepatocellular carcinoma (HCC) and liver cirrhosis are associated with high mortality worldwide. Currently, alpha-fetoprotein (AFP) is used as a standard serum marker for the detection of HCC, but its sensitivity and specificity are unsatisfactory, and optimal diagnostic markers for cirrhosis are lacking. We previously reported that growth differentiation factor 15 (GDF15) was significantly induced in HCV-infected hepatocytes. This study aimed to investigate GDF15 expression and its correlation with hepatitis virus-related liver diseases. A total of 412 patients with various liver diseases were studied. Healthy and Mycobacterium tuberculosis-infected subjects were included as controls. Serum and tissue GDF15 levels were measured. Serum GDF15 levels were significantly increased in patients with HCC (6.66±0.67 ng/mL, p<0.0001) and cirrhosis (6.51±1.47 ng/mL, p<0.0001) compared with healthy controls (0.31±0.01 ng/mL), though the GDF15 levels in HBV and HCV carriers were moderately elevated (1.34±0.19 ng/mL and 2.13±0.53 ng/mL, respectively). Compared with HBV or HCV carriers, GDF15 had a sensitivity of 63.1% and a specificity of 86.6% at the optimal cut-off point of 2.463 ng/mL in patients with liver cirrhosis or HCC. In HCC patients, the area under the receiver operating curve was 0.84 for GDF15 and 0.76 for AFP, but 0.91 for the combined GDF15 and AFP. Serum GDF15 levels did not significantly differ between the high-AFP and low-AFP groups. GDF15 protein expression in HCC was significantly higher than that in the corresponding adjacent paracarcinomatous tissue and normal liver. Using a combination of GDF15 and AFP will improve the sensitivity and specificity of HCC diagnosis. Further research and the clinical implementation of serum GDF15 measurement as a biomarker for HCC and cirrhosis are recommended.
Asunto(s)
Carcinoma Hepatocelular/sangre , Carcinoma Hepatocelular/patología , Factor 15 de Diferenciación de Crecimiento/sangre , Cirrosis Hepática/sangre , Cirrosis Hepática/patología , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/patología , Adulto , Anciano , Biomarcadores , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/etiología , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepatitis B/sangre , Hepatitis B/complicaciones , Hepatitis B/virología , Hepatitis C/sangre , Hepatitis C/complicaciones , Hepatitis C/virología , Humanos , Inmunohistoquímica , Cirrosis Hepática/etiología , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/etiología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios Retrospectivos , Sensibilidad y Especificidad , alfa-FetoproteínasRESUMEN
OBJECTIVES: Hepatitis C virus (HCV) infects hepatocytes and causes liver damage. The aim of this study was to identify new classes of host-targeting anti-HCV compounds that may provide novel approaches for antiviral treatment regimens. METHODS: Cell culture-derived HCV (HCVcc), replicons and pseudoparticles were used in combination with high-throughput screening, reporter gene assays and cytotoxicity and signalling pathway analyses. RESULTS: A small-molecule inhibitor of HCV, N-(cyclopropyl(phenyl)methyl)thieno[2,3-d]pyrimidin-4-amine, designated IB-32, was identified by screening a compound library with a Jc1-luc HCVcc assay. By using various virus models, HCV replication was identified as the predominant step of IB-32's action. IB-32 inhibited HCVcc (genotype 2a) and HCV replicons (genotype 1b) at low nanomolar ranges (with IC50s of 40â±â8 and 100â±â15 nM, respectively). IB-32 was found to be non-toxic when tested against a panel of human cell lines in vitro at the effective antiviral dose. Mechanistically, IB-32 strongly inhibited STAT3 (Tyr705) phosphorylation, a necessary cellular factor for HCV replication and a pivotal therapeutic target for multiple cancers. Furthermore, the inhibition of HCV replication by IB-32 was augmented in cells with STAT3 knockdown. In contrast, the inhibitory effect of IB-32 was attenuated in cells overexpressing a constitutively active form of STAT3. CONCLUSION: The results presented here identify a promising STAT3-targeting anti-HCV therapeutic candidate. This novel small molecule could be further optimized and developed for use as both an antiviral and an anti-cancer drug.
Asunto(s)
Antivirales/aislamiento & purificación , Antivirales/farmacología , Hepacivirus/fisiología , Factor de Transcripción STAT3/antagonistas & inhibidores , Replicación Viral/efectos de los fármacos , Antivirales/toxicidad , Línea Celular , Supervivencia Celular/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Hepatocitos/virología , Ensayos Analíticos de Alto Rendimiento/métodos , HumanosRESUMEN
The recently identified human infections with a novel avian influenza H7N9 virus in China raise important questions regarding possible risk to humans. However, the entry properties and tropism of this H7N9 virus were poorly understood. Moreover, neuraminidase inhibitor resistant H7N9 isolates were recently observed in two patients and correlated with poor clinical outcomes. In this study, we aimed to elucidate the entry properties of H7N9 virus, design and evaluate inhibitors for H7N9 virus entry. We optimized and developed an H7N9-pseudotyped particle system (H7N9pp) that could be neutralized by anti-H7 antibodies and closely mimicked the entry process of the H7N9 virus. Avian, human and mouse-derived cultured cells showed high, moderate and low permissiveness to H7N9pp, respectively. Based on influenza virus membrane fusion mechanisms, a potent anti-H7N9 peptide (P155-185-chol) corresponding to the C-terminal ectodomain of the H7N9 hemagglutinin protein was successfully identified. P155-185-chol demonstrated H7N9pp-specific inhibition of infection with IC50 of 0.19 µM. Importantly, P155-185-chol showed significant suppression of A/Anhui/1/2013 H7N9 live virus propagation in MDCK cells and additive effects with NA inhibitors Oseltamivir and Zanamivir. These findings expand our knowledge of the entry properties of the novel H7N9 viruses, and they highlight the potential for developing a new class of inhibitors targeting viral entry for use in the next pandemic.
Asunto(s)
Subtipo H7N9 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/virología , Internalización del Virus/efectos de los fármacos , Animales , Células CHO , Línea Celular , Chlorocebus aethiops , Cricetulus , Perros , Evaluación Preclínica de Medicamentos , Células HeLa , Humanos , Células de Riñón Canino Madin Darby , Ratones , Células 3T3 NIH , Pruebas de Neutralización , Células VeroRESUMEN
Hepatitis C virus (HCV) infection is a major cause of severe liver disease. Interferon (IFN)/ribavirin treatment remains the standard therapeutic regimen for HCV infection in most countries. IFN-stimulated genes are believed to contribute to antiviral effects. However, emerging evidence suggests that microRNAs (miRNAs), a class of noncoding small RNAs, are involved in the control of viral infection. Here, we systematically profiled the hepatocyte expression of a set of 750 miRNAs in response to alpha interferon (IFN-α) and interleukin-28B (IL-28B) treatments. The anti-HCV activity of differentially expressed miRNAs was evaluated using cell culture-derived HCV in vitro. The results demonstrate that let-7b had a significant anti-HCV effect by inhibiting HCV replication and viral protein translation in human hepatoma cells. In particular, we show that the inhibition of let-7b attenuated the anti-HCV effects of IFN-α and IL-28B. Furthermore, we show that the host factor insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a target of let-7b. IGF2BP1 was required for HCV replication, and its expression was downregulated by IFN-α and IL-28B. Deletion of the wild-type seed region of let-7b abolished its antiviral activity. Finally, we demonstrate that other let-7 family miRNAs were able to inhibit HCV and to suppress IGF2BP1 expression. In conclusion, we provide an example of a host miRNA regulated by type I and type III IFNs that inhibits HCV replication and infectivity by targeting host targets. These results highlight the important role of miRNAs in the host antiviral immune response and provide a novel candidate for anti-HCV therapy.
Asunto(s)
Hepacivirus/efectos de los fármacos , Interferón-alfa/farmacología , Interleucinas/farmacología , MicroARNs/genética , MicroARNs/metabolismo , Proteínas de Unión al ARN/metabolismo , Antivirales/farmacología , Secuencia de Bases , Línea Celular , Regulación hacia Abajo , Perfilación de la Expresión Génica , Hepacivirus/genética , Hepacivirus/fisiología , Hepatitis C/genética , Hepatitis C/inmunología , Hepatitis C/terapia , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Hepatocitos/virología , Ensayos Analíticos de Alto Rendimiento , Humanos , Interferones , Proteínas de Unión al ARN/antagonistas & inhibidores , Proteínas de Unión al ARN/genética , Replicación Viral/efectos de los fármacosRESUMEN
The cytokine interleukin-28B (IL-28B) has potential antiviral properties and regulatory roles in adaptive cellular immunity. A genome-wide association study identified a single nucleotide polymorphism near the IL-28B gene that strongly predicts response to hepatitis C treatment with interferon and ribavirin. In this study, we produced human serum albumin (HSA) fused to interleukin-28B (HSA-IL28B) in an attempt to determine the effects of albumin fusion on anti-Hepatitis C virus (HCV) activity and protein stability. HSA-IL28B was expressed at high levels in the yeast expression system we used and was easily purified. The biological activities of IL-28B were only retained when HSA was fused at the N-terminus. Compared with the native IL-28B, HSA-IL28B showed improved protein stability. HSA-IL28B inhibited HCV infection through the membrane receptors IL28R1 and IL10R2. Additionally, we demonstrated that HSA-IL28B was able to induce interferon-stimulated genes, phosphorylate intracellular STAT1, and act in restricted cell types. Our findings highlight the potential clinical applications of the fusion protein during virus infection and for immune regulation.
Asunto(s)
Antivirales/metabolismo , Hepacivirus/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Factores Inmunológicos/genética , Interleucinas/genética , Albúmina Sérica/genética , Antivirales/inmunología , Antivirales/farmacología , Línea Celular , Regulación de la Expresión Génica/efectos de los fármacos , Genes Reporteros , Hepacivirus/genética , Hepacivirus/crecimiento & desarrollo , Hepatocitos/virología , Humanos , Factores Inmunológicos/inmunología , Factores Inmunológicos/farmacología , Interferones/biosíntesis , Interferones/inmunología , Interleucinas/inmunología , Interleucinas/farmacología , Luciferasas/genética , Luciferasas/metabolismo , Pichia/genética , Pichia/metabolismo , Isoformas de Proteínas/genética , Isoformas de Proteínas/inmunología , Estabilidad Proteica , Estructura Terciaria de Proteína , Receptores de Interleucina/genética , Receptores de Interleucina/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/farmacología , Factor de Transcripción STAT1/genética , Factor de Transcripción STAT1/inmunología , Albúmina Sérica/inmunología , Albúmina Sérica/farmacologíaRESUMEN
Chronic infection by hepatitis C virus (HCV) is a cause of the global burden of liver diseases. HCV entry into hepatocytes is a complicated and multistep process that represents a promising target for antiviral intervention. The recently reported amphipathic α-helical virucidal peptide (C5A) from the HCV NS5A protein suggests a new category of antiviral drug candidates. In this study, to identify C5A-like HCV inhibitors, synthetic peptides derived from the C5A-corresponding NS5 protein region of selected Flaviviridae viruses were evaluated for their anti-HCV activities. A peptide from GB virus A (GBV-A), but not other flaviviruses, demonstrated an inhibitory effect on HCV infection. Through a series of sequence optimizations and modifications of the peptide helicity and hydrophobicity, we obtained a peptide designated GBVA10-9 with highly potent anti-HCV activity. GBVA10-9 suppressed infection with both cell culture-derived and pseudotyped HCV in vitro, and the 50% cell culture inhibitory concentration ranged from 20 nM to 160 nM, depending on the genotypic origin of the envelope proteins. GBVA10-9 had no detectable effects on either HCV attachment to Huh7.5.1 cells or viral RNA replication. No virucidal activity was found with GBVA10-9, suggesting an action mechanism distinct from that of C5A. The inhibitory effect of GBVA10-9 appeared to occur at the postbinding step during viral entry. Taken together, the results with GBVA10-9 demonstrated a potent activity for blocking HCV entry that might be used in combination with other antivirals directly targeting virus-encoded enzymes. Furthermore, GBVA10-9 also provides a novel tool to dissect the detailed mechanisms of HCV entry.
Asunto(s)
Antivirales/aislamiento & purificación , Productos Biológicos/aislamiento & purificación , Virus GB-A/genética , Hepacivirus/efectos de los fármacos , Péptidos/farmacología , Proteínas no Estructurales Virales/farmacología , Internalización del Virus/efectos de los fármacos , Antivirales/farmacología , Productos Biológicos/farmacología , Línea Celular , Evaluación Preclínica de Medicamentos , Hepacivirus/fisiología , Humanos , Concentración 50 Inhibidora , Pruebas de Sensibilidad Microbiana , Péptidos/genética , Proteínas no Estructurales Virales/genéticaRESUMEN
UNLABELLED: Hepatitis C virus (HCV) entry is a complicated process that requires multiple host factors, such as CD81, scavenger receptor BI, claudin-1 (CLDN1), and occludin. The interaction of virus and cellular entry factors represents a promising target for novel anti-HCV drug development. In this study, we sought to identify peptide inhibitors for HCV entry by screening a library of overlapping peptides covering the four above-mentioned entry factors. An 18-amino acid peptide (designated as CL58) that was derived from the CLDN1 intracellular and first transmembrane region inhibited both de novo and established HCV infection in vitro. Unlike previously reported peptides corresponding to CLDN1 extracellular loops, CL58 did not alter the normal distribution of CLDN1 and was not cytotoxic in vitro at concentrations nearly 100-fold higher than the effective antiviral dose. The inhibitory effect of CL58 appeared to occur at a late step during viral entry, presumably after initial binding. Finally, overexpressed CL58 was able to interact with HCV envelope proteins. CONCLUSION: We identified a novel CLDN1-derived peptide that inhibits HCV entry at a postbinding step. The findings expand our knowledge of the roles that CLDN1 play in HCV entry and highlight the potential for developing a new class of inhibitors targeting the viral entry process.
Asunto(s)
Antivirales/farmacología , Hepacivirus/efectos de los fármacos , Hepatitis C/prevención & control , Proteínas de la Membrana/farmacología , Péptidos/farmacología , Internalización del Virus/efectos de los fármacos , Secuencia de Aminoácidos , Antivirales/síntesis química , Antivirales/metabolismo , Línea Celular Tumoral , Claudina-1 , Diseño de Fármacos , Glicoproteínas/metabolismo , Hepacivirus/crecimiento & desarrollo , Hepacivirus/metabolismo , Hepatitis C/metabolismo , Hepatitis C/virología , Humanos , Proteínas de la Membrana/síntesis química , Proteínas de la Membrana/metabolismo , Datos de Secuencia Molecular , Péptidos/síntesis química , Péptidos/metabolismo , Uniones Estrechas/efectos de los fármacos , Uniones Estrechas/metabolismo , Uniones Estrechas/virología , Proteínas Virales/metabolismoRESUMEN
OBJECTIVES: Interleukin 28B (IL28B) genetic variation has been recently reported as a potent predictor of hepatitis C virus (HCV) response to interferon (IFN) therapy. The aim of this study was to produce recombinant human IL28B (rhIL28B) in yeast and explore the action mechanisms of rhIL28B as a novel anti-HCV agent. METHODS: A simple and efficient protocol for producing rhIL28B in the methylotrophic yeast Pichia pastoris was developed. The anti-HCV activity, induction of IFN-stimulated genes (ISGs), receptor usage and cellular responsiveness of rhIL28B were characterized. RESULTS: The yield of secreted rhIL28B was optimized to 200 mg/L, and soluble rhIL28B that was approximately 95% pure was achieved using a one-step ion-exchange purification procedure. rhIL28B inhibited HCV propagation in Huh7.5.1 cells with an IC(50) of 0.15 × 10(-3) mg/L. Treatment of hepatoma cells with rhIL28B resulted in the phosphorylation of STAT1 within 1 h and expression of ISGs. The HCV inhibitory effects of rhIL28B were antagonized by the antibody neutralization of receptors IL10R2 and IL28R1. The combination of rhIL28B and ribavirin synergistically inhibited HCV production in cell culture. Importantly, compared with the broad-spectrum activity of IFN-α, we demonstrated restricted cell-type responsiveness of rhIL28B in liver, lung and prostate cells. CONCLUSIONS: This study established an easy and highly efficient approach for the production of rhIL28B with potent in vitro antiviral activity and restricted cell tropism, and thus provides a novel antiviral candidate for improving the treatment of HCV-infected patients.
Asunto(s)
Antivirales/farmacología , Hepacivirus/crecimiento & desarrollo , Factores Inmunológicos/farmacología , Interleucinas/farmacología , Línea Celular , Cromatografía por Intercambio Iónico , Sinergismo Farmacológico , Perfilación de la Expresión Génica , Hepatocitos/virología , Humanos , Factores Inmunológicos/genética , Factores Inmunológicos/aislamiento & purificación , Concentración 50 Inhibidora , Interferones , Interleucinas/genética , Interleucinas/aislamiento & purificación , Pichia/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacología , Ribavirina/farmacología , Replicación Viral/efectos de los fármacosRESUMEN
The Armadillo (ARM)-repeat domain is a 42-amino acid protein-protein interaction motif present in many eukaryotic proteins. ARM-repeat proteins function in many cellular processes, including cytoskeletal regulation, nucleo-cytoplasmic trafficking, and transcriptional regulation. More than 100 genes encoding ARM-repeat proteins are predicted to exist in the Arabidopsis thaliana genome; however, most of them have unknown biological functions. Using map-based cloning, we isolated a novel recessive loss-of-function mutant, lfr-1, with developmental and morphological defects at the vegetative stage in the cotyledons and true leaves, and during the reproductive phase in the flowers and siliques. Complementation experiments and an analysis of the T-DNA insertion mutant lfr-2 revealed that LFR was responsible for all of the mutant phenotypes. LFR encodes a protein with three putative ARM-repeat domains that tends to cluster in the nucleus as discrete rounded speckles. LFR was broadly expressed while LFR was largely concentrated in the stem apex and root tip. Our data suggest that LFR is a novel nuclear-localized ARM-repeat protein that functions in leaf and flower development in Arabidopsis.